Skip to content

IORT in Local Advanced Laryngocarcinoma

Study of Safety and Feasibility With or Without Intraoperative Radiation in Local Advanced Laryngocarcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04278638
Acronym
ILAL
Enrollment
120
Registered
2020-02-20
Start date
2018-01-01
Completion date
2023-12-01
Last updated
2020-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal Neoplasms

Brief summary

The incidence of laryngeal cancer accounts for about 1 \ 5% of the total body tumors. For the surgical treatment of laryngeal cancer, the development trend of laryngocarcinoma treatment is to improve the local control rate, preserve the laryngeal function of patients as far as possible, and improve the life quality of patients. The efficacy, safety and feasibility of intraoperative radiotherapy (IORT) in head and neck cancer has been demonstrated in multiple institutional (3-5) studies to optimize local control. It is still unclear whether IORT can improve the local control and have efficacy, safety and feasibility in clinic. The purpose of this study was to observe the efficacy, safety and feasibility of IORT in local advanced laryngocarcinoma .

Interventions

RADIATIONIORT

IORT in surgery of laryngocarcinoma

PROCEDUREsurgery

total laryngectomy or hemilaryngectomy

External radiotherapy

Sponsors

Tianjin First Central Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. adults over the age of 18; 2. radiographic or pathological diagnosis of local advanced laryngocarcinoma (according to NCCN guidelines); 3. the expected survival time ≥ 3 months; 4. sign informed consent for treatment and research with self-knowledge.

Exclusion criteria

1. there is distant metastasis; 2. pregnant women; 3. patients with CT/MRI contraindications; 4. the patient fails to receive treatment and/or follow-up as scheduled; 5. bad fluid and organ function decompensation; 6. multiple primary cancers; 7. patients participating in other trials.

Design outcomes

Primary

MeasureTime frameDescription
2-year local recurrence rate2 yearIn this study, no matter whether distant metastases occurred, if there was the presence of any anastomotic or lateral node recurrences, it was defined as local recurrence. Criteria for local recurrence include (1) MRI results suggests local tumor recurrence, (2)Laryngoscopy indicates local tumor recurrence.

Secondary

MeasureTime frameDescription
tissue necrosis2 yearsCompare the risk of tissue necrosis as determined visually by the Laryngoscope at 2 years after treatment in patients with local advanced laryngocarcinoma treated with or without IORT.
2-year disease free survival2 yearsCompare 2-year disease free survival in patients with local advanced laryngocarcinoma treated with or without IORT. Criteria for disease free survival means MRI and laryngoscopy (PET-CT if possible) indicate tumor free.
fibrosis2 yearsCompare the risk of fibrosis as determined visually by the Laryngoscope at 2 years after treatment in patients with local advanced laryngocarcinoma treated with or without IORT.
time of wound healingup to 1 monthCompare the time of wound healing after surgery in patients with local advanced laryngocarcinoma treated with or without IORT.
2-year overall survival2 yearsCompare 2-year overall survival in patients with local advanced laryngocarcinoma treated with or without IORT.

Other

MeasureTime frameDescription
pharyngeal fistula3 monthsPharyngeal fistula means that saliva is stored in subcutaneous or subincisional tissues, resulting in abscess cavity rupture to the skin or incision margin, making the hypopharyngeal and esophageal lumen communicate with the skin to form a sinus tract, through which saliva or food can spill out to the skin, forming a skin fistula.

Countries

China

Contacts

Primary ContactXinyuan Gong
gxy0007@163.com+8613436640313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026